参苓白术散治疗腹泻型肠易激综合征的系统评价及临床观察
发布时间：2019-04-15 14:08
【摘要】：目的:系统评价参苓白术散治疗腹泻型肠易激综合征的有效性安全性及观察参苓白术散治疗腹泻型肠易激综合征临床疗效。方法:1.系统评价部分:运用系统评价方法,检索参苓白术散治疗腹泻型肠易激综合征的随机对照试验,筛选合格研究,评价研究质量,应用国际循证医学协作网提供的统计软件Revman5.3统计数据,应用Jadad评分法进行质量评价。临床按试验措施的不同分亚组对所收集数据进行异质性检验和Meta-分析。2.临床研究部分:选择观察对象共60例,随机分为试验组和对照组,试验组30例,对照组30例。试验组给予参苓白术散水煎剂;对照组给予匹维溴铵片合培菲康胶囊,4周为一疗程。一疗程后观察临床疗效。结果:1.系统评价部分:经筛选最终纳入18项研究,共1446例,根据试验措施不同分为两组,结果显示参苓白术散在治疗D-IBS临床总有效率、临床症状总积分、腹痛、腹泻方面的疗效均优于对照组,均有统计学意义和临床意义且无严重不良反应。上述结果说明参苓白术散加减治疗D-IBS较为安全可靠,为临床用药提供了参考。2.临床研究部分:临床综合疗效方面,实验组总有效率96.7%,对照组总有效率86.7%,试验组总有效率高于对照组,经分析,两组存在显著性差异(P0.05),在临床综合疗效改善方面试验组优于对照组。试验组与对照组比较,证候总积分比较有显著差异(P0.05),说明在中医证候总积分改善方面,试验组优于对照组。结论:1.通过系统评价分析参苓白术散加减能提高D-IBS的临床疗效,但由于本系统评价纳入研究质量低且样本量小,药物安全性不明确,尚需高质量随机对照试验进一步评价。2.临床研究表明参苓白术散治疗腹泻型肠易激综合征优于匹维溴铵片合培菲康胶囊。
[Abstract]:Aim: to evaluate the efficacy and safety of Shenling Baizhu Powder in the treatment of diarrhea irritable bowel syndrome and to observe the clinical efficacy of Shenling Baizhu Powder in the treatment of diarrhea irritable bowel syndrome. Methods: 1. In the part of systematic evaluation, the randomized controlled trials of Shenling Baizhu Powder in the treatment of diarrhea irritable bowel syndrome were searched, qualified studies were screened, and the quality of the study was evaluated. The Revman5.3 statistical data provided by the International Collaborative Network for evidence-based Medicine (EBM) were used to evaluate the quality by using the Jadad scoring method. Clinical heterogeneity test and Meta- analysis of collected data according to different subgroups of trial measures. 2. Clinical study: 60 cases were randomly divided into experimental group and control group, 30 cases in experimental group and 30 cases in control group. The experimental group was given Shenling Baizhu powder decoction, and the control group was given Peiwei ammonium bromide tablet and Peifeikang capsule for 4 weeks as a course of treatment. The clinical curative effect was observed after a course of treatment. Results: 1. In the part of systematic evaluation: 1446 cases were divided into two groups according to different test measures. The results showed that Shenling Baizhu powder was effective in the treatment of D-IBS, the total score of clinical symptoms, abdominal pain, and total score of clinical symptoms, and the results showed that Shenling Baizhu powder was effective in the treatment of D-IBS. The curative effect of diarrhea was better than that of control group, with statistical and clinical significance and no serious adverse reaction. The above results indicate that Shenling Baizhu Powder is safe and reliable in the treatment of D-IBS, which provides a reference for clinical use of drugs. 2. Clinical research part: the clinical comprehensive curative effect aspect, the experimental group total effective rate is 96.7%, the control group total effective rate is 86.7%, the experimental group total effective rate is higher than the control group, through the analysis, the two groups have significant difference (P0.05), The experimental group was superior to the control group in the improvement of clinical comprehensive curative effect. Compared with the control group, there was significant difference between the experimental group and the control group (P0.05), which indicated that the experimental group was better than the control group in the improvement of the total integral of TCM syndrome. Conclusions: 1. Through the systematic evaluation and analysis of Shenling Baizhu Powder can improve the clinical efficacy of D-IBS, but due to the low quality and small sample size of this system evaluation study, drug safety is not clear, it needs to be further evaluated by high-quality randomized controlled trial. 2. Clinical studies show that Shenling Baizhu Powder is superior to Pivoxil tablets in the treatment of diarrhea-type irritable bowel syndrome.
【学位授予单位】：山东中医药大学
【学位级别】：硕士
【学位授予年份】：2016
【分类号】：R259
本文编号：2458214
[Abstract]:Aim: to evaluate the efficacy and safety of Shenling Baizhu Powder in the treatment of diarrhea irritable bowel syndrome and to observe the clinical efficacy of Shenling Baizhu Powder in the treatment of diarrhea irritable bowel syndrome. Methods: 1. In the part of systematic evaluation, the randomized controlled trials of Shenling Baizhu Powder in the treatment of diarrhea irritable bowel syndrome were searched, qualified studies were screened, and the quality of the study was evaluated. The Revman5.3 statistical data provided by the International Collaborative Network for evidence-based Medicine (EBM) were used to evaluate the quality by using the Jadad scoring method. Clinical heterogeneity test and Meta- analysis of collected data according to different subgroups of trial measures. 2. Clinical study: 60 cases were randomly divided into experimental group and control group, 30 cases in experimental group and 30 cases in control group. The experimental group was given Shenling Baizhu powder decoction, and the control group was given Peiwei ammonium bromide tablet and Peifeikang capsule for 4 weeks as a course of treatment. The clinical curative effect was observed after a course of treatment. Results: 1. In the part of systematic evaluation: 1446 cases were divided into two groups according to different test measures. The results showed that Shenling Baizhu powder was effective in the treatment of D-IBS, the total score of clinical symptoms, abdominal pain, and total score of clinical symptoms, and the results showed that Shenling Baizhu powder was effective in the treatment of D-IBS. The curative effect of diarrhea was better than that of control group, with statistical and clinical significance and no serious adverse reaction. The above results indicate that Shenling Baizhu Powder is safe and reliable in the treatment of D-IBS, which provides a reference for clinical use of drugs. 2. Clinical research part: the clinical comprehensive curative effect aspect, the experimental group total effective rate is 96.7%, the control group total effective rate is 86.7%, the experimental group total effective rate is higher than the control group, through the analysis, the two groups have significant difference (P0.05), The experimental group was superior to the control group in the improvement of clinical comprehensive curative effect. Compared with the control group, there was significant difference between the experimental group and the control group (P0.05), which indicated that the experimental group was better than the control group in the improvement of the total integral of TCM syndrome. Conclusions: 1. Through the systematic evaluation and analysis of Shenling Baizhu Powder can improve the clinical efficacy of D-IBS, but due to the low quality and small sample size of this system evaluation study, drug safety is not clear, it needs to be further evaluated by high-quality randomized controlled trial. 2. Clinical studies show that Shenling Baizhu Powder is superior to Pivoxil tablets in the treatment of diarrhea-type irritable bowel syndrome.
【学位授予单位】：山东中医药大学
【学位级别】：硕士
【学位授予年份】：2016
【分类号】：R259
【参考文献】
相关期刊论文 前10条
1 陈君臻;;经方诊治腹泻型肠易激综合征[J];亚太传统医药;2015年17期
2 张永顺;李雪青;朱叶珊;;灵龟八法贴敷治疗腹泻型肠易激综合征30例[J];河南中医;2015年08期
3 夏齐国;冯鑫鑫;黄建华;陈雷;应荐;;推拿配合药饼灸改善脾肾阳虚腹泻型肠易激综合征患者腹痛症状的临床观察[J];浙江中医杂志;2015年07期
4 甄杰武;文慧华;;参苓白术散治疗腹泻型肠易激综合征的临床研究[J];中医临床研究;2015年19期
5 袁瑞兴;;缩脾法在腹泻型肠易激综合征中临床应用体会[J];实用中西医结合临床;2015年06期
6 朱创键;;双歧三联活菌胶囊联合参苓白术散对腹泻型IBS患者血浆SS和NPY水平影响及疗效观察[J];中国微生态学杂志;2015年05期
7 金欣;陈勤;;桔梗的药理作用研究新进展[J];现代中药研究与实践;2015年02期
8 王建梅;;针刺为主治疗肠易激综合征43例临床观察[J];中国民间疗法;2014年12期
9 董桂芬;;参苓白术散加减治疗肠易激综合症35例[J];光明中医;2014年11期
10 武建华;;温针灸治疗腹泻型肠易激综合征疗效观察[J];中国中医药信息杂志;2014年11期
，本文编号：2458214
本文链接：https://www.wllwen.com/zhongyixuelunwen/2458214.html
最近更新
教材专著
